Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840453 | 0.82 | L3MBTL1 (0.55) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL13883778 | 0.81 | FFAR1 (0.47) | SMN1; SMN2MAPTGAAHPGDLMNA | |
| SCHEMBL13883865 | 0.81 | MAPT (0.54) | ALDH1A1MAPTGAANPC1RAB9A | |
| SCHEMBL1569202 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL28155818 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL379217 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL2413521 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL3077683 | 0.81 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1MAPTGAAHPGD | |
| SCHEMBL7693031 | 0.79 | ALOX5 (0.57) | SMN1; SMN2MAPTHPGDLMNATP53 | |
| SCHEMBL13197099 | 0.78 | FBP1 (0.50) | SMN1; SMN2ALDH1A1MAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | GALAPAGOS NV (BE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242661-A1 | Novel compounds useful for the treatment of degenerative & inflammatory diseases | PDE4A, PDE7B, PDE4B | SMN1; SMN2 2362/4885ALDH1A1 130/4885MAPT 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.